List of Excipients in Branded Drug LEVOCETIRIZINE DIHYDROCHLORIDE

« Back to Dashboard

Generic Drugs Containing LEVOCETIRIZINE DIHYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Teva Pharmaceuticals USA Inc	levocetirizine dihydrochloride	0093-7701	CELLULOSE, MICROCRYSTALLINE
Teva Pharmaceuticals USA Inc	levocetirizine dihydrochloride	0093-7701	HYPROMELLOSE 2910
Teva Pharmaceuticals USA Inc	levocetirizine dihydrochloride	0093-7701	LACTOSE MONOHYDRATE

What are the Most Frequently-Used Excipients in LEVOCETIRIZINE DIHYDROCHLORIDE?

# Of NDCs	Excipient
9	ACETIC ACID
1	ANHYDROUS LACTOSE
90	CELLULOSE, MICROCRYSTALLINE

Levocetirizine Dihydrochloride Excipient Strategy and Commercial Opportunities

Last updated: August 3, 2026

Levocetirizine dihydrochloride is a mature, low-cost antihistamine with limited active-ingredient patent protection and substantial formulation competition. Commercial opportunity is concentrated in excipient-enabled differentiation: pediatric liquids, orally disintegrating tablets, sugar-free and alcohol-free products, rapid-dissolution formats, combination products, and private-label OTC supply. The strongest strategy is to select excipients that improve taste, manufacturability, stability, and patient convenience without creating unnecessary regulatory or intellectual-property risk.

What is levocetirizine dihydrochloride?

Levocetirizine dihydrochloride is the R-enantiomer of cetirizine and a selective H1 histamine-receptor antagonist. It is used for allergic rhinitis and chronic idiopathic urticaria. The standard adult and adolescent dose is 5 mg once daily, with lower dosing or dose adjustment required in certain pediatric and renal-impairment populations.[1]

Attribute	Commercial relevance
Active ingredient	Levocetirizine dihydrochloride
Therapeutic class	Second-generation antihistamine
Common brand	Xyzal
Typical tablet strength	5 mg
Common liquid strength	0.5 mg/mL
Administration	Oral tablet, oral solution, orally disintegrating tablet in some markets
Pharmacology	Selective H1 antagonist
Sedation profile	Lower than first-generation antihistamines, but somnolence remains a labeled risk
Regulatory status	Mature approved small-molecule drug
Biosimilar pathway	Not applicable
Primary competition	Cetirizine, loratadine, desloratadine, fexofenadine

Levocetirizine is generally suitable for conventional immediate-release solid and liquid dosage forms. Its low dose creates a high excipient-to-drug ratio, making taste masking, content uniformity, and dose-measurement accuracy more important than raw drug loading.

What excipients are used in levocetirizine tablets?

Conventional levocetirizine tablets typically use a direct-compression or wet-granulation system containing a filler, binder, disintegrant, glidant, lubricant, and film-coating materials.

Core tablet excipient system

Functional role	Candidate excipients	Strategic purpose
Diluent	Microcrystalline cellulose, lactose monohydrate, mannitol, dibasic calcium phosphate	Provides tablet mass and compression performance
Binder	Povidone, pregelatinized starch, hydroxypropyl cellulose	Improves granule and tablet strength
Disintegrant	Crospovidone, croscarmellose sodium, sodium starch glycolate	Supports rapid tablet breakup
Glidant	Colloidal silicon dioxide	Improves powder flow and content uniformity
Lubricant	Magnesium stearate, sodium stearyl fumarate	Reduces ejection force and tooling adhesion
Film former	Hypromellose, polyvinyl alcohol	Improves appearance, handling, and swallowability
Plasticizer	Polyethylene glycol, triethyl citrate	Reduces coating brittleness
Opacifier or colorant	Titanium dioxide, iron oxides, approved lakes	Product identification and appearance

The commercial product selected for a generic or private-label product should be driven by manufacturing platform rather than by the lowest unit excipient price. A low-cost formulation that produces sticking, picking, variable disintegration, or coating defects can increase total cost through rejected batches and slower line speeds.

Which excipient strategy is strongest for immediate-release tablets?

A robust baseline is microcrystalline cellulose with crospovidone, colloidal silicon dioxide, and magnesium stearate, followed by a thin hypromellose film coat. This system supports direct compression, high-throughput manufacturing, and rapid disintegration.

Direct-compression strategy

Direct compression is attractive because it reduces processing steps and avoids aqueous exposure. A representative development platform may use:

• Microcrystalline cellulose or mannitol as the principal filler
• Crospovidone as the primary disintegrant
• Colloidal silicon dioxide for flow
• Magnesium stearate or sodium stearyl fumarate for lubrication
• Hypromellose-based film coating

The low 5 mg dose creates a content-uniformity challenge. Geometric dilution, ordered mixing, or co-processing with a carrier may be needed. The formulation should be tested for segregation after transfer, hopper residence, and vibration because the active ingredient represents a small fraction of total blend mass.

Lactose-based strategy

Lactose monohydrate can reduce cost and support conventional tablet manufacture. It may be less attractive where the target population includes consumers who avoid lactose or where a lactose-free label is commercially valuable. Lactose compatibility should be evaluated against the selected amine-containing active and storage conditions.

Mannitol-based strategy

Mannitol can support a premium positioning, especially for orally disintegrating or chewable products. It provides a cooling mouthfeel and lower hygroscopicity than many polyols. Its higher cost and potential tablet capping or compression behavior must be balanced against the retail benefit.

What excipients are best for orally disintegrating levocetirizine tablets?

Orally disintegrating tablets can create differentiation in pediatric, geriatric, and travel-use segments. The principal technical requirements are rapid disintegration, acceptable mouthfeel, mechanical strength, and taste masking.

A suitable platform may contain:

• Mannitol for bulk and mouthfeel
• Microcrystalline cellulose or silicified microcrystalline cellulose for compactability
• Crospovidone for rapid disintegration
• Low levels of colloidal silicon dioxide for flow
• Aspartame, sucralose, or acesulfame potassium for sweetness
• Flavoring agents such as berry, grape, or mint
• A taste-masking polymer or coated drug particles where bitterness is significant

Levocetirizine is administered at a low dose, which allows taste-masking technologies to use a relatively small mass of coated active. Polymer coating options include ethylcellulose, hypromellose, methacrylate copolymers, and lipid-based systems. The coating must release the drug promptly after swallowing and should not materially delay dissolution under immediate-release testing.

A commercial ODT product needs more than rapid disintegration. It should also demonstrate low friability, resistance to moisture uptake, and reliable blister-pack performance. Aluminum-aluminum blister packaging may be justified for a moisture-sensitive formulation, although it raises packaging cost.

What excipients are used in levocetirizine oral solution?

Liquid products create the clearest opportunity for pediatric and family-oriented differentiation. A typical oral solution may contain purified water, a sweetener, a humectant, a buffer, a preservative, flavor, and a viscosity modifier.

Liquid formulation options

Formulation objective	Excipient options	Commercial consideration
Sweetness	Sucralose, sodium saccharin, sorbitol, sucrose	Sugar-free labeling favors sucralose or saccharin
Body and mouthfeel	Glycerin, sorbitol, propylene glycol	Excess polyol can cause gastrointestinal effects
Preservation	Methylparaben, propylparaben, potassium sorbate, sodium benzoate	Selection depends on pH, target market, and preservative efficacy
pH control	Citric acid/sodium citrate, acetate buffers, phosphate buffers	Controls stability, taste, and preservative performance
Viscosity	Hydroxyethylcellulose, xanthan gum, sodium carboxymethylcellulose	Supports dose uniformity and sensory quality
Flavor	Fruit, berry, vanilla, mint	Masks bitterness and supports pediatric adherence
Chelation	Disodium EDTA	May improve stability where trace metals contribute to degradation
Container protection	Amber glass or light-protective plastic	Reduces photodegradation risk

The branded Xyzal oral solution labeling identifies a multi-excipient liquid system including sweetening, buffering, preservative, flavor, and viscosity-related components.[2] Generic developers can use a different excipient architecture, but the product must meet FDA requirements for inactive-ingredient safety, stability, microbial quality, and dose uniformity.

A preservative-free formulation may have commercial value for sensitive consumers, but it increases microbial-control requirements and may require unit-dose packaging. A single-dose cup or stick-pack format can support travel and pediatric use while raising packaging and filling costs.

Which formulation opportunities offer the highest commercial value?

The most practical opportunities are products that solve a clear consumer or pharmacy problem.

Pediatric sugar-free oral solution

A sugar-free, alcohol-free, dye-free oral solution can compete in pediatric allergy care. The formulation should use a calibrated oral syringe rather than a household spoon. Important development targets include:

• Accurate delivery at low volumes
• Low viscosity variation across storage
• Acceptable taste after repeated dosing
• Preservative efficacy
• Child-resistant packaging
• Stability after opening

Orally disintegrating tablet

An ODT can compete against standard tablets where swallowing difficulty or convenience matters. The product can be packaged in unit-dose blisters and marketed for use without water, subject to applicable labeling rules.

Chewable tablet

Chewables may be attractive for children and consumers who prefer an alternative to liquid dosing. The main risks are bitterness, friability, dental-sugar concerns, and dose uniformity. Mannitol, xylitol, or sorbitol can provide a sugar-free platform, but polyol load should be assessed for gastrointestinal tolerance.

Combination products

Levocetirizine can be combined with another active ingredient for allergy or upper-airway symptoms. Combination products create a larger commercial proposition but also increase regulatory, clinical, labeling, and intellectual-property complexity. Potential combinations require careful review of duplicate antihistamine exposure, sedation, renal dosing, and ingredient-specific safety.

Premium sensory formulation

A product with improved flavor, no artificial color, no sugar, no alcohol, and a convenient dosing device can command a higher retail price than a standard generic. The value is commercial rather than patent-based and depends on brand execution, pharmacy placement, and consumer retention.

What FDA regulatory status applies to levocetirizine products?

Levocetirizine is an approved small-molecule drug. In the United States, generic tablets and oral solutions are generally submitted through abbreviated new drug applications under section 505(j) of the Federal Food, Drug, and Cosmetic Act. Generic products must demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug, subject to dosage-form-specific requirements.[3]

Xyzal was switched to nonprescription status in the United States, creating both prescription-generic and OTC opportunities.[4] An OTC product must comply with the applicable monograph or obtain an approved application, depending on the product and regulatory pathway.

Inactive-ingredient considerations

FDA’s Inactive Ingredient Database can guide excipient selection, but prior use does not eliminate the need to assess maximum daily exposure, dosage form, age group, route, and concentration.[5] Pediatric liquids require particular scrutiny for:

• Propylene glycol exposure
• Benzyl alcohol exclusion or control
• Paraben use
• Polyol-associated gastrointestinal effects
• Artificial color and flavor sensitivity
• Aspartame-related labeling requirements
• Alcohol content
• Sorbitol and fructose-related warnings where applicable

What patents protect levocetirizine products?

The foundational composition and enantiomer protection for levocetirizine is expired in major markets. The drug therefore has limited freedom-to-operate value from the active ingredient itself. Current differentiation is more likely to rely on formulation, manufacturing, packaging, delivery-device, or combination-product claims.

Patent and exclusivity position

IP category	Current commercial relevance
Levocetirizine active ingredient	Foundational protection expired
Original branded formulation	Generally weak as a barrier to conventional generics
Pediatric oral solution	Possible formulation and packaging claims, but difficult to enforce broadly
ODT and taste masking	Potentially protectable if claims are technically narrow and supported
Combination products	May retain claims depending on active ingredients and jurisdiction
Manufacturing process	Can protect cost-efficient production if non-obvious and difficult to design around
Device and packaging	May support incremental protection
Regulatory exclusivity	No meaningful new-molecule exclusivity remains

The FDA Orange Book should be checked for current listed patents and exclusivity associated with the relevant reference product and dosage form.[6] Orange Book listing does not establish that every claim is enforceable, and an absence of a listed patent does not eliminate non-Orange-Book patent risk.

When does levocetirizine lose exclusivity?

Levocetirizine has already lost core market exclusivity in the United States and other major pharmaceutical markets. Generic entry is established, and commercial competition is primarily based on price, channel access, dosage form, supply reliability, and brand positioning.

Paragraph IV challenges and litigation status

Paragraph IV certification is generally relevant to an ANDA applicant challenging an unexpired Orange Book patent. Because the foundational levocetirizine patents have expired, a new Paragraph IV dispute would most likely concern a later formulation, combination, or method-of-use patent rather than the active ingredient itself.

There is no biosimilar risk because levocetirizine is a chemically synthesized small molecule, not a biologic. The relevant competitive risk is generic substitution and OTC/private-label competition.

No major current litigation or settlement agreement should be assumed to create a material barrier to standard levocetirizine tablets or oral solutions without a current docket and Orange Book review.

How strong is the patent estate for levocetirizine formulations?

The patent estate is weak for ordinary immediate-release tablets and stronger only where the product includes a technically differentiated platform.

Relative patent strength

Product concept	Patent strength	Main reason
Standard 5 mg tablet	Low	Mature dosage form with extensive prior art
Conventional oral solution	Low to moderate	Broad claims are vulnerable; narrow stability claims may remain
Sugar-free pediatric solution	Moderate	Differentiation depends on precise composition and stability data
ODT with taste masking	Moderate	Coating, particle size, disintegration, and release claims may be available
Modified-release product	Moderate to high	Technical complexity increases patent potential, but clinical value is uncertain
Combination product	Moderate	Claim scope depends on active ingredients and indication
Packaging or dosing device	Moderate	Protection is often narrow and design-around risk is high
Manufacturing process	Moderate	Valuable if it produces measurable cost or quality advantages

A formulation patent is strongest when it covers a measurable technical effect, such as improved stability, reduced bitterness, faster disintegration, lower impurity formation, or improved bioavailability. A patent that merely lists common excipients at routine concentrations is more exposed to obviousness and written-description challenges.

What manufacturing and IP barriers affect commercial entry?

The main barriers are operational rather than fundamental patent barriers.

Manufacturing barriers

• Low-dose blend uniformity
• Powder segregation during transfer
• Tablet sticking and picking
• Taste masking without delayed dissolution
• Microbial control in oral liquids
• Preservative efficacy throughout shelf life
• Moisture protection for ODTs
• Accurate pediatric dose delivery
• Flavor consistency across batches
• Supply continuity for specialty polymers and flavors

A manufacturer with established liquid-filling, ODT compression, and blister-pack capabilities can enter faster than a company that must build those platforms. Contract manufacturing organizations with pediatric liquid infrastructure may offer the best route for an OTC launch.

Geographic coverage

Core generic competition is established across the United States, European Union, Canada, India, and other regulated and semi-regulated markets. Commercial opportunity varies by geography:

• United States: OTC brand, store-brand, pediatric liquid, and convenience formats
• European Union: pharmacy and national-market generic competition, with country-specific reimbursement dynamics
• India: high generic density and price competition, with strong demand for syrups and combination products
• Middle East and Latin America: private-label, tender, and family-oriented liquid opportunities
• Emerging markets: supply reliability, price, and palatability often matter more than novel delivery technology

Formulation filings should be evaluated country by country. A US formulation patent does not automatically provide enforceable protection in Europe, India, or Latin America.

How does levocetirizine compare with competing antihistamines?

Drug	Key competitive advantage	Excipient opportunity
Levocetirizine	Low dose, established efficacy, broad generic availability	ODT, pediatric liquid, sugar-free and premium sensory products
Cetirizine	Strong familiarity and low price	Similar liquid and chewable opportunities; greater direct price pressure
Loratadine	Long-established OTC use and broad retail presence	Chewables, dissolving tablets, and combination products
Desloratadine	Branded and generic positioning in allergy care	Pediatric liquid and low-sugar products
Fexofenadine	Low-sedation positioning	Large-dose tablet and liquid formulation advantages

Levocetirizine’s strongest commercial position is not a new pharmacologic claim. It is a differentiated user experience supported by reliable manufacturing and retail distribution.

What licensing deals and partnership models are available?

Because the active ingredient is mature and widely genericized, licensing value is more likely to arise from enabling technology than from levocetirizine itself.

Potential partnership structures include:

1. A branded OTC company licenses a taste-masking platform for a pediatric or ODT product.
2. A generic manufacturer licenses a ready-to-file oral-solution formulation.
3. A consumer-health company acquires a private-label product with retail distribution.
4. A contract manufacturer supplies a complete dossier, filling process, and packaging configuration.
5. A formulation company licenses a combination product or delivery device.

A technology license should be valued against formulation performance, regulatory readiness, freedom to operate, manufacturing scale, and geographic rights. Royalty economics are unlikely to support a large payment for a conventional tablet formulation with no meaningful patent or channel advantage.

What revenue exposure exists for levocetirizine products?

Revenue exposure is concentrated in high-volume, low-margin products. Standard tablets are vulnerable to rapid price erosion after generic entry. Higher-margin opportunities include:

• Branded OTC products
• Store-brand supply agreements
• Pediatric oral solutions
• Unit-dose liquid packaging
• ODTs and chewables
• Allergy-season promotional bundles
• Multi-country regulatory dossiers
• Hospital and pharmacy tender supply

The main financial risks are ingredient and packaging commoditization, retailer concentration, seasonal demand, recalls caused by liquid microbial failure, and substitution by cetirizine or loratadine.

Key Takeaways

• Levocetirizine dihydrochloride is a mature generic and OTC antihistamine with expired core active-ingredient protection.
• Standard immediate-release tablets offer limited patent and margin protection.
• The strongest excipient opportunities are pediatric liquids, ODTs, chewables, sugar-free systems, and premium taste profiles.
• Microcrystalline cellulose, crospovidone, mannitol, colloidal silicon dioxide, and hypromellose provide a practical solid-dose development platform.
• Oral solutions require careful control of pH, preservatives, sweeteners, viscosity, microbial quality, and pediatric excipient exposure.
• No biosimilar pathway applies. Generic substitution is the principal competitive risk.
• Formulation patents can support differentiation only when tied to measurable technical advantages.
• Commercial value depends more on dosage form, retail channel, manufacturing reliability, and sensory performance than on the levocetirizine molecule.

FAQs

Is levocetirizine dihydrochloride suitable for a sugar-free oral solution?

Yes. Sucralose, sodium saccharin, glycerin, sorbitol, and suitable flavor systems can support a sugar-free formulation. Preservative efficacy, viscosity, taste, and pediatric tolerability must be demonstrated.

Can levocetirizine be formulated as a fast-dissolving tablet?

Yes. Mannitol, crospovidone, microcrystalline cellulose, and taste-masking technology can support an orally disintegrating tablet. Moisture protection and mechanical strength are key development issues.

Does levocetirizine require a biosimilar application?

No. Levocetirizine is a chemically synthesized small molecule. Generic products use abbreviated pathways rather than biosimilar applications.

Are levocetirizine excipients patentable?

An excipient itself is generally not enough to create meaningful protection. Patent value is stronger when a specific excipient combination produces a demonstrated improvement in dissolution, stability, palatability, dose uniformity, or manufacturing performance.

What is the best commercial levocetirizine product opportunity?

A sugar-free, alcohol-free pediatric oral solution with a calibrated syringe or a palatable ODT is generally more defensible commercially than another conventional 5 mg tablet. The preferred option depends on manufacturing capability, target market, and retail positioning.

References

1. U.S. Food and Drug Administration. (2017). Xyzal (levocetirizine dihydrochloride) prescribing information.
2. DailyMed. (n.d.). Xyzal levocetirizine dihydrochloride oral solution labeling. U.S. National Library of Medicine.
3. U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions: Content and format.
4. U.S. Food and Drug Administration. (2017). FDA approves OTC Xyzal allergy medication.
5. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database.
6. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.